High expression of miR-210 predicts poor survival in patients with breast cancer: A meta-analysis

Gene

Volumn 507, Issue 2, 2012, Pages 135-138

  Hong, Liu ^a   Yang, Jianjun ^a   Han, Yu ^a   Lu, Qun ^b   Cao, Jun ^b   Syed, Labiq ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; MiR 210; Survival

Indexed keywords

MICRORNA 210;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CANCER TISSUE; COCHRANE LIBRARY; CONFIDENCE INTERVAL; GENE EXPRESSION; HAZARD RATIO; HUMAN; MEDLINE; META ANALYSIS (TOPIC); PREDICTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, NEOPLASM; UP-REGULATION;

EID: 84865192626     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.07.025     Document Type: Article

References (47)

1. Buffa F.M., et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 2011, 71:5635-5645.
2. Camps C., et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 2008, 14:1340-1348.
3. Caporali A., Emanueli C. MicroRNA regulation in angiogenesis. Vascul. Pharmacol. 2011, 55:79-86.
4. Chan S.Y., Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle 2010, 9:1072-1083.
5. Clark C.E., Taylor R.S., Shore A.C., Ukoumunne O.C., Campbell J.L. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet 2012, 379:905-914.
6. Cortez M.A., Welsh J.W., Calin G.A. Circulating MicroRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 2012, 195:151-161.
7. Crosby M.E., Devlin C.M., Glazer P.M., Calin G.A., Ivan M. Emerging roles of microRNAs in the molecular responses to hypoxia. Curr. Pharm. Des. 2009, 15:3861-3866.
8. Devlin C., Greco S., Martelli F., Ivan M. miR-210: more than a silent player in hypoxia. IUBMB Life 2011, 63:94-100.
9. Duncavage E., Goodgame B., Sezhiyan A., Govindan R., Pfeifer J. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J. Thorac. Oncol. 2010, 5:1755-1763.
10. Favaro E., et al. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and Krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One 2010, 5:e10345.
11. Ferracin M., Querzoli P., Calin G.A., Negrini M. MicroRNAs: toward the clinic for breast cancer patients. Semin. Oncol. 2011, 38:764-775.
12. Foekens J.A., et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13021-13026.
13. Fu X., et al. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur. J. Clin. Invest. 2011, 41:1245-1253.
14. Gao L.B., et al. The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis. Breast Cancer Res. Treat. 2011, 125:571-574.
15. Gee H.E., et al. hsa-miR-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 2010, 116:2148-2158.
16. Gee H.E., et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br. J. Cancer 2011, 104:1168-1177.
17. Greither T., et al. Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int. J. Cancer 2012, 130:1230-1235.
18. Hagman Z., et al. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int. J. Cancer 2010, 127:2768-2776.
19. Hong L., et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann. Surg. 2010, 251:1056-1063.
20. Hong L., et al. The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin. Biol. Ther. 2010, 10:1693-1701.
21. Ishibashi O., et al. Hydroxysteroid (17-β) dehydrogenase 1 is dysregulated by miR-210 and miR-518c that are aberrantly expressed in preeclamptic placentas: a novel marker for predicting preeclampsia. Hypertension 2012, 59:265-273.
22. Ivan M., Harris A.L., Martelli F., Kulshreshtha R. Hypoxia response and microRNAs: no longer two separate worlds. J. Cell. Mol. Med. 2008, 12:1426-1431.
23. Jung E.J., et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012, 118:2603-2614.
24. Lawrie C.H., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141:672-675.
25. Lee B.L., Liedke P.E., Barrios C.H., Simon S.D., Finkelstein D.M., Goss P.E. Breast cancer in Brazil: present status and future goals. Lancet Oncol. 2012, 13:e95-e102.
26. Liu R., et al. The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One 2012, 3:e33987.
27. Nikitina E.G., Urazova L.N., Stegny V.N. MicroRNAs and human cancer. Exp. Oncol. 2012, 34:2-8.
28. Quero L., Dubois L., Lieuwes N.G., Hennequin C., Lambin P. miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiother. Oncol. 2011, 101:203-208.
29. Radojicic J., Zaravinos A., Vrekoussis T., Kafousi M., Spandidos D.A., Stathopoulos E.N. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011, 10:507-517.
30. Reedijk M. Notch signaling and breast cancer. Adv. Exp. Med. Biol. 2012, 727:241-257.
31. Roa W., et al. Identification of a new microRNA expression profile as a potential cancer screening tool. Clin. Invest. Med. 2010, 33:E124.
32. Rothé F., et al. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 2011, 6:e20980.
33. Satzger I., et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int. J. Cancer 2010, 126:2553-2562.
34. Scapoli L., et al. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int. J. Immunopathol. Pharmacol. 2010, 23:1229-1234.
35. Shen J., Jiang F. Applications of microRNAs in the diagnosis and prognosis of lung cancer. Expert Opin. Med. Diagn. 2012, 6:197-207.
36. Smith R.A., Jedlinski D.J., Gabrovska P.N., Weinstein S.R., Haupt L., Griffiths L.R. A genetic variant located in miR-423 is associated with reduced breast cancer risk. Cancer Genomics Proteomics 2012, 9:115-118.
37. Sun J.Y., et al. MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting β-catenin. Biochem. Biophys. Res. Commun. 2012, 420:787-792.
38. Tan X., et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin. Cancer Res. 2011, 17:6802-6811.
39. Toyama T., et al. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn. J. Clin. Oncol. 2012, 42:256-263.
40. VanderWalde A., Hurria A. Early breast cancer in the older woman. Clin. Geriatr. Med. 2012, 28:73-91.
41. Volinia S., et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3024-3029.
42. Wang J., et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. (Phila.) 2009, 2:807-813.
43. Xu W., et al. Effects of common polymorphisms rs11614913 in miR-196a2 and rs2910164 in miR-146a on cancer susceptibility: a meta-analysis. PLoS One 2011, 6:e20471.
44. Yang W., Lee D.Y., Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. Int. J. Physiol. Pathophysiol. Pharmacol. 2011, 3:140-155.
45. Yu L., et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 2011, 127:2870-2878.
46. Zeng L., et al. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front. Biosci. 2011, 3:1265-1272.
47. Zhang Y., et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol. Cancer 2012, 11:23.